UnitedHealth Group (UNH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on July 29, might help the stock move higher if these key numbers are better than expect ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric th ...

Group 1: Company Performance - UnitedHealth Group (UNH) closed at $307.70, with a daily increase of +1.31%, outperforming the S&P 500's loss of 0.07% [1] - Over the past month, shares of UnitedHealth Group have appreciated by 0.17%, while the Medical sector experienced a loss of 1.3% [1] Group 2: Upcoming Earnings - The earnings report for UnitedHealth Group is scheduled for July 29, 2025, with expected earnings of $5.08 per share, reflecting a year-over-year decline of 25.29% [2] - Revenue is forecasted to be $111.86 billion, indicating a growth of 13.16% compared to the same quarter last year [2] Group 3: Annual Estimates - For the annual period, earnings are anticipated to be $21.85 per share, with revenue projected at $449.46 billion, representing declines of -21.01% and growth of +12.29%, respectively [3] Group 4: Analyst Estimates - Recent modifications to analyst estimates for UnitedHealth Group reflect evolving short-term business trends, with positive revisions indicating analyst optimism [4] - The Zacks Rank system, which incorporates estimate changes, provides a rating system for investors [5] Group 5: Zacks Rank and Valuation - UnitedHealth Group currently holds a Zacks Rank of 5 (Strong Sell), with the consensus EPS estimate moving 2.81% lower over the last 30 days [6] - The company has a Forward P/E ratio of 13.9, which is a premium compared to the industry average of 13.02, and a PEG ratio of 1.45, compared to the industry average of 0.86 [7] Group 6: Industry Overview - The Medical - HMOs industry, part of the Medical sector, has a Zacks Industry Rank of 91, placing it in the top 37% of over 250 industries [8]

UnitedHealth Group (UNH) ended the recent trading session at $302.01, demonstrating a -1.69% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.22%. On the other hand, the Dow registered a gain of 0.08%, and the technology-centric Nasdaq decreased by 0.51%. Coming into today, shares of the largest U.S. health insurer had gained 3.55% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 0.45%. The investment community will be ...

The most recent trading session ended with UnitedHealth Group (UNH) standing at $298.17, reflecting a +0.02% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 0.4%. At the same time, the Dow added 0.28%, and the tech-heavy Nasdaq gained 0.39%.Coming into today, shares of the largest U.S. health insurer had lost 27.55% in the past month. In that same time, the Medical sector lost 3.41%, while the S&P 500 gained 6.69%.The investment community will be paying close att ...

The Joint Corp. (JYNT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.06, delivering no surprise.Over the last four quarters, the company has not been ab ...

Group 1 - Adaptive Biotechnologies (ADPT) is outperforming its peers in the Medical sector, gaining about 47% year-to-date compared to the sector's average loss of 4.8% [4] - The Zacks Rank for Adaptive Biotechnologies is 2 (Buy), indicating a positive earnings outlook and strong analyst sentiment, with a 5.5% increase in the consensus estimate for full-year earnings [3][4] - The Medical group ranks 3 within the Zacks Sector Rank, which evaluates 16 different sector groups based on the average Zacks Rank of individual stocks [2] Group 2 - Adaptive Biotechnologies is part of the Medical - Biomedical and Genetics industry, which has seen an average loss of 8% this year, further highlighting ADPT's strong performance [6] - Another outperforming stock in the Medical sector is Centene (CNC), which has gained 3.9% year-to-date, with a Zacks Rank of 2 (Buy) and a 4.4% increase in the consensus EPS estimate [5][7] - The Medical - HMOs industry, where Centene belongs, has experienced a decline of 14% since the beginning of the year, contrasting with the performance of Adaptive Biotechnologies [7]

Investors in The Joint Corp. (JYNT) need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $7.50 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also ...

Group 1: Earnings Performance - Cigna reported quarterly earnings of $6.74 per share, exceeding the Zacks Consensus Estimate of $6.39 per share, and showing an increase from $6.47 per share a year ago, representing an earnings surprise of 5.48% [1] - The company posted revenues of $65.45 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.66%, compared to year-ago revenues of $57.25 billion [2] - Over the last four quarters, Cigna has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Cigna shares have increased approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $7.17 on revenues of $61.56 billion, and for the current fiscal year, it is $29.61 on revenues of $252.36 billion [7] Group 3: Industry Context - The Medical - HMOs industry, to which Cigna belongs, is currently ranked in the top 17% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Cigna's stock performance [5] - The Zacks Rank for Cigna is currently 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

Select Medical (SEM) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.22%. A quarter ago, it was expected that this hospital and rehabilitation center operator would post earnings of $0.19 per share when it actually produced earnings of $0.18, delivering a surprise of -5.26%.Over th ...